Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.

Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp. after receiving results from the SUSTAIN clinical trial, a Phase II clinical trial evaluating SelG1 for the reduction of vaso-occlusive pain among sickle cell disease (SCD) patients. The results will be presented at the 58th American Society of Hematology (ASH) Annual Meeting on December 4.

Highest Paid Medical Technicians in America

Natee K Jindakum/

Importance of Acquisition

“With this acquisition, Novartis is able to leverage its leadership in hematology research to advance development of a potential new treatment option for patients living with this debilitating condition,” boasted Bruno Strigini, Novartis Oncology CEO.

There are millions of patients suffering from SCD around the world. Amid this, the treatment options currently available are still limited — particularly for a common complication such as vaso-occlusive pain crises.

SCD is a hereditary, lifelong blood disease. Vaso-occlusive pain crises are episodic occurrences among SCD patients. They happen when sickle-shaped red blood cells (RBCs) hamper blood flow through the blood vessels.

According to Scott Rollins, Ph.D., former Selexys Pharmaceuticals CEO and President, the acquisition also signifies an important milestone in the development of SelG1, a potential first-in-class therapy for vaso-occlusive pain crises among SCD patients.

The transaction will cost as much as $665 million in upfront and milestone payments combined.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

On Monday, Novartis AG (ADR) (NYSE:NVS) has also recognized the GOLD 2017 report publication.

The GOLD 2017 report has highly recommended the first-line use of dual bronchodilators in treating most symptomatic chronic obstructive pulmonary disease (COPD) patients. Primarily, it aims to help healthcare providers in implementing better COPD management programs constantly.

Vasant Narasimhan, Novartis Chief Medical Officer (CMO) and Global Head of Drug Development, has emphasized that the GOLD 2017 report marks an important milestone in improving COPD patient care throughout the world.

The new recommendations can potentially lead to the shift to dual bronchodilators from traditional inhaled corticosteroid (ICS)/LABA combinations for the first-line treatment of symptomatic COPD patients regardless of potential risks. The GOLD 2017 report has backed these recommendations with substantial evidences demonstrating no significant harms or risks.

Presently, Ultibro Breezhaler is the only dual bronchodilator with proven superior efficacy over most ICS/LABA combinations for the said indication.

Novartis AG (ADR) (NYSE:NVS) has closed at $70.13 on Monday.

Follow Novartis A G (NYSE:NVS)
Trade (NYSE:NVS) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.